The Open Cardiovascular Medicine Journal

ISSN: 1874-1924 ― Volume 13, 2019

Efficacy of Aliskiren/Hydrochlorothiazide Combination for the Treatment of Hypertension: A Meta-Analytical Approach

Manuel P Morgado a, b, *, Sandra A Rolo b, Miguel Castelo-Branco a, b
a Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal
b Hospital Centre of Cova da Beira, E.P.E.,Quinta do Alvito, 6200-251 Covilhã, Portugal



Single-pill combinations of aliskiren/hydrochlorothiazide have recently been approved by the European Medicines Agency for the treatment of hypertension.


This study aimed to assess the antihypertensive efficacy of aliskiren/hydrochlorothiazide combination in reducing systolic and diastolic blood pressure in hypertensive patients.


A search in International Pharmaceutical Abstracts, MEDLINE, The Cochrane Library and ISI Web of Knowledge was performed from 2000 to November 2009, to identify randomized, double-blind, clinical trials using aliskiren/hydrochlorothiazide for the treatment of hypertension. Studies were included if they evaluated the antihypertensive efficacy of aliskiren/hydrochlorothiazide in patients with mild or moderate essential hypertension and age ≥ 18 years. The meta-analytical approach calculated the weighted average reductions of systolic and diastolic blood pressure for each daily dosage combination.


We included 5 clinical trials testing several combinations of aliskiren/hydrochlorothiazide and containing data on 5448 patients. In all studies blood pressure was assessed at inclusion (baseline) and after 8 weeks of therapy. Blood pressure reductions and control rates were significantly (p < 0.05) higher with the aliskiren/hydrochlorothiazide combinations than with placebo and the same doses of aliskiren or hydrochlorothiazide alone. The weighted mean reductions (mm Hg) from baseline of systolic and diastolic blood pressure for each aliskiren/hydrochlorothiazide combination were: -15.8/-10.3 (150/25 mg); -15.9/-11.8 (300/12.5 mg); -16.9/-11.6 (300/25 mg). Blood pressure control rates (%) for the above combinations were, at least, respectively: 43.8, 50.1 and 51.9.


Aliskiren/hydrochlorothiazide provided clinically significant additional blood pressure reductions and improved blood pressure control rates over aliskiren or hydrochlorothiazide monotherapy.

Keywords: Aliskiren;, aliskiren-hydrochlorothiazide;, combination therapy;, hypertension;, blood pressure;, antihypertensives..

Article Information

Identifiers and Pagination:

Year: 2011
Volume: 5
First Page: 6
Last Page: 14
Publisher Id: TOCMJ-5-6
DOI: 10.2174/1874192401105010006

Article History:

Received Date: 03/12/2010
Revision Received Date: 20/12/2010
Acceptance Date: 24/12/2010
Electronic publication date: 15/02/2011
Collection year: 2011

Article Metrics:

CrossRef Citations:

Total Statistics:

Full-Text HTML Views: 2195
Abstract HTML Views: 1041
PDF Downloads: 303
Total Views/Downloads: 3539

Unique Statistics:

Full-Text HTML Views: 538
Abstract HTML Views: 555
PDF Downloads: 189
Total Views/Downloads: 1282
Geographical View

© Morgado et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Health Sciences Research Centre, University of Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal; Tel: +351 275329072; Fax: +351 275329099; E-mail:


"I am very satisfied by all the services, friendly communication and the attention that was given to my manuscript. My sincere gratitude tou you and the entire team of Bentham Open"

Aristofanis Gikas
Health Centre of Kalivia, K
alivia, Attiki,

Browse Contents

Webmaster Contact:
Copyright © 2019 Bentham Open